Hans-Peter Hartung - Publications

Affiliations: 
Department of Neurology Heinrich-Heine-Universitat Dusseldorf, Germany 

222/323 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Cruz-Herranz A, Dietrich M, Hilla AM, Yiu HH, Levin MH, Hecker C, Issberner A, Hallenberger A, Cordano C, Lehmann-Horn K, Balk LJ, Aktas O, Ingwersen J, von Gall C, Hartung HP, et al. Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation. 16: 203. PMID 31684959 DOI: 10.1186/s12974-019-1583-4  0.4
2019 Albrecht P, Jansen A, Lee JI, Aktas O, Bigalke H, Hartung HP, Hefter H. Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 93: 768-769. PMID 31636233 DOI: 10.1212/WNL.0000000000008381  0.4
2019 Albrecht P, Jansen A, Lee JI, Ringelstein M, Aktas O, Hartung HP, Bigalke H, Hefter H. Author response: High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 93: 767-768. PMID 31636231 DOI: 10.1212/WNL.0000000000008378  0.4
2019 Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet (London, England). PMID 31495497 DOI: 10.1016/S0140-6736(19)31817-3  0.4
2019 Sinnecker T, Hadisurya J, Schneider-Hohendorf T, Schwab N, Wrede K, Gembruch O, Gold R, Hellwig K, Pilgram-Pastor S, Adams O, Albrecht P, Hartung HP, Aktas O, Kraemer M. Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. Bmc Neurology. 19: 190. PMID 31399069 DOI: 10.1186/s12883-019-1407-2  0.4
2019 Warnke C, Hartung HP. Big data in MS-What can we learn from large international observational studies such as MSBase? Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519868982. PMID 31397200 DOI: 10.1177/1352458519868982  0.52
2019 Lee JI, Gemerzki L, Boerker L, Guthoff R, Aktas O, Gliem M, Jander S, Hartung HP, Albrecht P. No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. Frontiers in Neurology. 10: 741. PMID 31354611 DOI: 10.3389/fneur.2019.00741  0.4
2019 Förster M, Graf J, Mares J, Aktas O, Hartung HP, Kremer D. Drug Treatment of Clinically Isolated Syndrome. Cns Drugs. 33: 659-676. PMID 31290079 DOI: 10.1007/s40263-019-00647-x  0.4
2019 Graf J, Ingwersen J, Lepka K, Albrecht P, Hartung HP, Ringelstein M, Aktas O. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. Acta Neurologica Scandinavica. PMID 31269227 DOI: 10.1111/ane.13144  0.4
2019 Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O. Clinical trials in multiple sclerosis: potential future trial designs. Therapeutic Advances in Neurological Disorders. 12: 1756286419847095. PMID 31205492 DOI: 10.1177/1756286419847095  0.52
2019 Schweitzer F, Laurent S, Fink GR, Barnett MH, Reddel S, Hartung HP, Warnke C. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Current Opinion in Neurology. PMID 30985373 DOI: 10.1097/WCO.0000000000000701  0.52
2019 Hartung HP, Graf J, Aktas O, Mares J, Barnett MH. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. Current Opinion in Neurology. PMID 30985371 DOI: 10.1097/WCO.0000000000000699  0.4
2019 Warnke C, Hartung HP. Challenging a concept: Pulsed treatment regimen-No risk of PML? Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519843232. PMID 30964427 DOI: 10.1177/1352458519843232  0.52
2019 Prozorovski T, Ingwersen J, Lukas D, Göttle P, Koop B, Graf J, Schneider R, Franke K, Schumacher S, Britsch S, Hartung HP, Küry P, Berndt C, Aktas O. Regulation of sirtuin expression in autoimmune neuroinflammation: induction of SIRT1 in oligodendrocyte progenitor cells. Neuroscience Letters. PMID 30953735 DOI: 10.1016/j.neulet.2019.04.007  0.4
2019 Aktas O, Hartung HP. CSI: MS. Tracing optic nerve involvement by standardized optical coherence tomography. Annals of Neurology. PMID 30900764 DOI: 10.1002/ana.25471  0.4
2019 Kraemer M, Schwitalla JC, Diesner F, Aktas O, Hartung HP, Berlit P. Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. Journal of Neurology. PMID 30868219 DOI: 10.1007/s00415-019-09277-1  0.4
2019 Graf J, Schwitalla JC, Albrecht P, Veltkamp R, Berlit P, Hartung HP, Aktas O, Kraemer M. Misdiagnoses and delay of diagnoses in Moyamoya angiopathy-a large Caucasian case series. Journal of Neurology. PMID 30805794 DOI: 10.1007/s00415-019-09245-9  0.4
2019 Dietrich M, Aktas O, Hartung HP, Albrecht P. Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. Current Opinion in Neurology. PMID 30694926 DOI: 10.1097/WCO.0000000000000675  0.4
2019 Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D. Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety. PMID 30607830 DOI: 10.1007/s40264-018-0782-8  0.52
2019 Graf J, Aktas O, Rejdak K, Hartung HP. Monoclonal Antibodies for Multiple Sclerosis: An Update. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. PMID 30604390 DOI: 10.1007/s40259-018-0327-9  0.4
2018 Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. PMID 30464031 DOI: 10.1212/WNL.0000000000006688  0.4
2018 Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, ... ... Hartung HP, et al. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology. 326: 19-27. PMID 30447419 DOI: 10.1016/j.jneuroim.2018.11.002  0.52
2018 Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, et al. Racial differences in neuromyelitis optica spectrum disorder. Neurology. PMID 30366977 DOI: 10.1212/WNL.0000000000006574  0.4
2018 Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurology(R) Neuroimmunology & Neuroinflammation. 5: e504. PMID 30345331 DOI: 10.1212/NXI.0000000000000504  0.4
2018 Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nature Reviews. Disease Primers. 4: 31. PMID 30310069 DOI: 10.1038/s41572-018-0027-2  0.4
2018 Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518771276. PMID 30307371 DOI: 10.1177/1352458518771276  0.4
2018 Graf J, Jansen L, Ingwersen J, Ringelstein M, Harmel J, Rybak J, Kolbe R, Rhöse L, Gemerzki L, Lee JI, Klistorner A, Guthoff R, Hartung HP, Aktas O, Albrecht P. Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. Annals of Clinical and Translational Neurology. 5: 952-961. PMID 30128319 DOI: 10.1002/acn3.593  0.4
2018 Leussink VI, Montalban X, Hartung HP. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. Cns Drugs. PMID 29992409 DOI: 10.1007/s40263-018-0536-2  0.32
2018 Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, Kohne Z, Küry P, Berndt C, Aktas O, Fischer D, Hartung HP, Albrecht P. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. Journal of Neuroinflammation. 15: 71. PMID 29514678 DOI: 10.1186/s12974-018-1111-y  0.4
2018 Kieseier BC, Hartung HP. Progress in Recognizing and Treating Polyneuropathy. Deutsches Arzteblatt International. 115: 81-82. PMID 29478434 DOI: 10.3238/arztebl.2018.0081  0.4
2018 Ingwersen J, De Santi L, Wingerath B, Graf J, Koop B, Schneider R, Hecker C, Schröter F, Bayer M, Engelke AD, Dietrich M, Albrecht P, Hartung HP, Annunziata P, Aktas O, et al. Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. Journal of Neurochemistry. PMID 29473171 DOI: 10.1111/jnc.14324  0.4
2017 Dietrich M, Cruz-Herranz A, Yiu H, Aktas O, Brandt AU, Hartung HP, Green A, Albrecht P. Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. Bmj Open Ophthalmology. 1: e000008. PMID 29354694 DOI: 10.1136/bmjophth-2016-000008  0.4
2017 Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, et al. Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology. 4: 909-914. PMID 29296620 DOI: 10.1002/acn3.491  0.52
2017 Graf J, Ringelstein M, Aktas O, Wattjes MP, Hartung HP. Fulminant intramedullary spinal cord sarcoidosis. Multiple Sclerosis and Related Disorders. 18: 47-48. PMID 29141820 DOI: 10.1016/j.msard.2017.09.010  0.4
2017 Rajabally YA, Stettner M, Kieseier BC, Hartung HP, Malik RA. CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nature Reviews. Neurology. PMID 28914883 DOI: 10.1038/nrneurol.2017.123  0.4
2017 Warnke C, Graf J, Hartung HP. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod. Multiple Sclerosis (Houndmills, Basingstoke, England). 23: 1176-1178. PMID 28749310 DOI: 10.1177/1352458517720045  0.52
2017 Ingenhoven K, Kramer D, Jensen PE, Hermanrud C, Ryner M, Deisenhammer F, Pallardy M, Menge T, Hartung HP, Kieseier BC, Bertotti E, Creeke P, Fogdell-Hahn A, Warnke C. Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta. Frontiers in Neurology. 8: 305. PMID 28729851 DOI: 10.3389/fneur.2017.00305  0.52
2017 Lepka K, Volbracht K, Bill E, Schneider R, Rios N, Hildebrandt T, Ingwersen J, Prozorovski T, Lillig CH, van Horssen J, Steinman L, Hartung HP, Radi R, Holmgren A, Aktas O, et al. Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. Glia. PMID 28618115 DOI: 10.1002/glia.23178  0.4
2017 Albrecht P, Blasberg C, Ringelstein M, Müller AK, Finis D, Guthoff R, Kadas EM, Lagreze W, Aktas O, Hartung HP, Paul F, Brandt AU, Methner A. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Journal of Neurology. PMID 28584914 DOI: 10.1007/s00415-017-8532-x  0.4
2017 Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 28572277 DOI: 10.1136/jnnp-2017-315603  0.4
2017 Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 28490505 DOI: 10.1136/jnnp-2016-315298  0.52
2017 Warnke C, Hartung HP. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517705480. PMID 28481191 DOI: 10.1177/1352458517705480  0.52
2017 Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, ... ... Hartung HP, et al. Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. Plos One. 12: e0170395. PMID 28170401 DOI: 10.1371/journal.pone.0170395  0.52
2017 Szepanowski F, Donaldson DM, Hartung HP, Mausberg AK, Kleinschnitz C, Kieseier BC, Stettner M. Dimethyl fumarate accelerates peripheral nerve regeneration via activation of the anti-inflammatory and cytoprotective Nrf2/HO-1 signaling pathway. Acta Neuropathologica. PMID 28108787 DOI: 10.1007/s00401-017-1676-z  0.4
2016 Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Arzteblatt International. 113: 879-886. PMID 28130920 DOI: 10.3238/arztebl.2016.0879  0.52
2016 Bachelet D, Hässler S, Mbogning C, Link J, Ryner M, Ramanujam R, Auer M, Hyldgaard Jensen PE, Koch-Henriksen N, Warnke C, Ingenhoven K, Buck D, Grummel V, Lawton A, Donnellan N, ... ... Hartung HP, et al. Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. Plos One. 11: e0162752. PMID 27806057 DOI: 10.1371/journal.pone.0162752  0.52
2016 Jarius S, Ringelstein M, Haas J, Serysheva II, Komorowski L, Fechner K, Wandinger KP, Albrecht P, Hefter H, Moser A, Neuen-Jacob E, Hartung HP, Wildemann B, Aktas O. Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflammation. 13: 278. PMID 27776522 DOI: 10.1186/s12974-016-0737-x  0.4
2016 Meyer Zu Horste G, Cordes S, Pfaff J, Mathys C, Mausberg AK, Bendszus M, Pham M, Hartung HP, Kieseier BC. Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis. Plos One. 11: e0164099. PMID 27711247 DOI: 10.1371/journal.pone.0164099  0.4
2016 Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, et al. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology. PMID 27590291 DOI: 10.1212/WNL.0000000000003169  0.72
2016 Menge T, Dubey D, Warnke C, Hartung HP, Stüve O. Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics. PMID 27552111 DOI: 10.1080/14737175.2016.1227242  0.52
2016 Schneider R, Koop B, Schröter F, Cline J, Ingwersen J, Berndt C, Hartung HP, Aktas O, Prozorovski T. Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. Molecular Neurodegeneration. 11: 53. PMID 27480121 DOI: 10.1186/s13024-016-0117-0  0.72
2016 Lepka K, Berndt C, Hartung HP, Aktas O. Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases. Frontiers in Cell and Developmental Biology. 4: 63. PMID 27446915 DOI: 10.3389/fcell.2016.00063  0.4
2016 Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K. Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. Jama Neurology. PMID 27380540 DOI: 10.1001/jamaneurol.2016.1451  0.52
2016 Leussink VI, Hartung HP, Kieseier BC, Stettner M. Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies. Therapeutic Advances in Neurological Disorders. 9: 336-43. PMID 27366241 DOI: 10.1177/1756285616641583  0.4
2016 Szepanowski F, Derksen A, Steiner I, Meyer Zu Hörste G, Daldrup T, Hartung HP, Kieseier BC. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling. Journal of Neuroinflammation. 13: 143. PMID 27283020 DOI: 10.1186/s12974-016-0612-9  0.4
2016 Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27207462 DOI: 10.1177/1352458516643600  0.72
2016 Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology. PMID 27177997 DOI: 10.1007/s00415-016-8146-8  0.72
2016 Buerth C, Mausberg AK, Heininger MK, Hartung HP, Kieseier BC, Ernst JF. Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide. Plos One. 11: e0155082. PMID 27159446 DOI: 10.1371/journal.pone.0155082  0.4
2016 Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, ... ... Hartung HP, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 27113605 DOI: 10.1136/jnnp-2015-312601  0.72
2016 Leussink VI, Hartung HP, Stüve O, Kieseier BC. Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'. Journal of Neurology. PMID 27060083 DOI: 10.1007/s00415-016-8110-7  0.72
2016 Cree BA, Hartung HP. Steering through complexity: management approaches in multiple sclerosis. Current Opinion in Neurology. PMID 27058222 DOI: 10.1097/WCO.0000000000000332  0.72
2016 Aktas O, Albrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Current Opinion in Neurology. PMID 27035900 DOI: 10.1097/WCO.0000000000000327  0.72
2016 Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P. Recent achievements in stem cell-mediated myelin repair. Current Opinion in Neurology. PMID 27035898 DOI: 10.1097/WCO.0000000000000323  0.72
2016 Leussink VI, Stettner M, Warnke C, Hartung HP. Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system. Journal of the Peripheral Nervous System : Jpns. PMID 26968589 DOI: 10.1111/jns.12169  0.52
2016 Kremer D, Göttle P, Hartung HP, Küry P. Pushing Forward: Remyelination as the New Frontier in CNS Diseases. Trends in Neurosciences. PMID 26964504 DOI: 10.1016/j.tins.2016.02.004  0.72
2016 Ingwersen J, Wingerath B, Graf J, Lepka K, Hofrichter M, Schröter F, Wedekind F, Bauer A, Schrader J, Hartung HP, Prozorovski T, Aktas O. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. Journal of Neuroinflammation. 13: 48. PMID 26920550 DOI: 10.1186/s12974-016-0512-z  0.72
2016 Weber A, Zimmermann C, Mausberg AK, Dehmel T, Kieseier BC, Hartung HP, Hofstetter HH. Pseudomonas aeruginosa and its bacterial components influence the cytokine response in thymocytes and splenocytes. Infection and Immunity. PMID 26902726 DOI: 10.1128/IAI.00905-15  0.72
2016 Stettner M, Hinrichs L, Guthoff R, Bairov S, Petropoulos IN, Warnke C, Hartung HP, Malik RA, Kieseier BC. Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. Annals of Clinical and Translational Neurology. 3: 88-100. PMID 26900579 DOI: 10.1002/acn3.275  0.52
2016 Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet (London, England). PMID 26827074 DOI: 10.1016/S0140-6736(15)01314-8  0.72
2016 Ingwersen J, Aktas O, Hartung HP. Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 13: 47-57. PMID 26701666 DOI: 10.1007/s13311-015-0412-4  0.72
2015 Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 26666258 DOI: 10.1177/1352458515620934  0.72
2015 Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Wegner B, Hellwig K, Pache F, Ruprecht K, Havla J, Krumbholz M, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses. Annals of Neurology. PMID 26537743 DOI: 10.1002/ana.24554  0.72
2015 Warnke C, Olsson T, Hartung HP. PML: The Dark Side of Immunotherapy in Multiple Sclerosis. Trends in Pharmacological Sciences. 36: 799-801. PMID 26497099 DOI: 10.1016/j.tips.2015.09.006  0.72
2015 Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, ... ... Hartung HP, et al. Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics. PMID 26475045 DOI: 10.1136/jmedgenet-2015-103442  0.72
2015 Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, et al. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. Jama Neurology. 1-8. PMID 26458124 DOI: 10.1001/jamaneurol.2015.2742  0.72
2015 Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology. 85: 1694-701. PMID 26453645 DOI: 10.1212/WNL.0000000000002099  0.72
2015 Kremer D, Hartung HP, Küry P. Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1616-7. PMID 26432852 DOI: 10.1177/1352458515608693  0.72
2015 Meyer Zu Horste G, Derksen A, Stassart R, Szepanowski F, Thanos M, Stettner M, Boettcher C, Lehmann HC, Hartung HP, Kieseier BC. Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System. Journal of Neuropathology and Experimental Neurology. 74: 1077-85. PMID 26426268 DOI: 10.1097/NEN.0000000000000253  0.72
2015 Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier BC. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain and Behavior. 5: e00326. PMID 26355945 DOI: 10.1002/brb3.326  0.72
2015 Schröder K, Finis D, Harmel J, Ringelstein M, Hartung HP, Geerling G, Aktas O, Guthoff R. Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Multiple Sclerosis and Related Disorders. 4: 406-8. PMID 26346788 DOI: 10.1016/j.msard.2015.06.015  0.72
2015 Gliem M, Klotz L, van Rooijen N, Hartung HP, Jander S. Hyperglycemia and PPARγ Antagonistically Influence Macrophage Polarization and Infarct Healing After Ischemic Stroke. Stroke; a Journal of Cerebral Circulation. 46: 2935-42. PMID 26337971 DOI: 10.1161/STROKEAHA.115.010557  0.72
2015 Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, ... ... Hartung HP, et al. [Current aspects of therapy conversion for multiple sclerosis]. Der Nervenarzt. 86: 1236-47. PMID 26269289 DOI: 10.1007/s00115-015-4368-8  0.72
2015 Hartung HP, Gold R. [People in view, brain in focus]. Der Nervenarzt. 86: 923-4. PMID 26208545 DOI: 10.1007/s00115-014-4247-8  0.72
2015 Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller AK, Finis D, Guthoff R, Bergholz R, Duning T, Krämer M, Paul F, Brandt A, Oberwahrenbrock T, Mikolajczak J, ... ... Hartung HP, et al. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology. 85: 610-8. PMID 26203089 DOI: 10.1212/WNL.0000000000001852  0.72
2015 Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, et al. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. Journal of Neuroimmunology. 285: 68-70. PMID 26198921 DOI: 10.1016/j.jneuroim.2015.05.019  0.72
2015 Albrecht P, Blasberg C, Lukas S, Ringelstein M, Müller AK, Harmel J, Kadas EM, Finis D, Guthoff R, Aktas O, Hartung HP, Paul F, Brandt AU, Berlit P, Methner A, et al. Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology. 85: 521-7. PMID 26180140 DOI: 10.1212/WNL.0000000000001832  0.72
2015 Gliem M, Krammes K, Liaw L, van Rooijen N, Hartung HP, Jander S. Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia. 63: 2198-207. PMID 26148976 DOI: 10.1002/glia.22885  0.72
2015 Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, et al. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology. 85: 29-39. PMID 26024899 DOI: 10.1212/WNL.0000000000001706  0.72
2015 Tzekova N, Heinen A, Bunk S, Hermann C, Hartung HP, Reipert B, Küry P. Immunoglobulins stimulate cultured Schwann cell maturation and promote their potential to induce axonal outgrowth. Journal of Neuroinflammation. 12: 107. PMID 26022648 DOI: 10.1186/s12974-015-0331-7  0.72
2015 Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends in Pharmacological Sciences. 36: 419-21. PMID 26003802 DOI: 10.1016/j.tips.2015.04.012  0.72
2015 Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung HP, Kieseier B, Gold R, Aktas O, Kleiter I. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. Jama Neurology. 72: 756-63. PMID 25985228 DOI: 10.1001/jamaneurol.2015.0533  0.72
2015 Heinen A, Beyer F, Tzekova N, Hartung HP, Küry P. Fingolimod induces the transition to a nerve regeneration promoting Schwann cell phenotype. Experimental Neurology. 271: 25-35. PMID 25957629 DOI: 10.1016/j.expneurol.2015.05.002  0.72
2015 Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Review of Neurotherapeutics. 15: 339-46. PMID 25800129 DOI: 10.1586/14737175.2015.1025755  0.72
2015 Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S. Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 449-54. PMID 25773662 DOI: 10.1007/s13311-015-0348-8  0.72
2015 Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, van Doorn PA, Dalakas MC, Latov N. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse. Muscle & Nerve. PMID 25728021 DOI: 10.1002/mus.24624  0.72
2015 Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, ... ... Hartung HP, et al. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1013-24. PMID 25680984 DOI: 10.1177/1352458514568827  0.52
2015 Prozorovski T, Schneider R, Berndt C, Hartung HP, Aktas O. Redox-regulated fate of neural stem progenitor cells. Biochimica Et Biophysica Acta. 1850: 1543-1554. PMID 25662818 DOI: 10.1016/j.bbagen.2015.01.022  0.72
2015 Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Annals of Clinical and Translational Neurology. 2: 43-55. PMID 25642434 DOI: 10.1002/acn3.152  0.52
2015 Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras CM, Kremer D, Hartung HP, Cate HS, Küry P. Oligodendroglial maturation is dependent on intracellular protein shuttling. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 906-19. PMID 25609610 DOI: 10.1523/JNEUROSCI.1423-14.2015  0.72
2015 Gibbs E, Karim ME, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs. Clinical Immunology (Orlando, Fla.). 157: 91-101. PMID 25543089 DOI: 10.1016/j.clim.2014.12.005  0.72
2015 Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Review of Clinical Immunology. 11: 93-108. PMID 25495182 DOI: 10.1586/1744666X.2015.992881  0.72
2015 Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1200-3. PMID 25480862 DOI: 10.1177/1352458514560926  0.72
2015 Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, ... ... Hartung HP, et al. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 1036-44. PMID 25392339 DOI: 10.1177/1352458514556296  0.72
2015 Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, et al. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 885-93. PMID 25392325 DOI: 10.1177/1352458514554052  0.72
2015 Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Journal of Neurology. 262: 326-36. PMID 25381458 DOI: 10.1007/s00415-014-7558-6  0.72
2015 Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 22-34. PMID 25344374 DOI: 10.1177/1352458514549398  0.72
2015 Hartung HP, Kappos L, Goodin DS, O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, et al. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b Journal of Neurology. DOI: 10.1007/s00415-015-7862-9  0.72
2015 Hartung HP. Neuromuscular Blocking Activity Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition. 1767-1781. DOI: 10.1007/978-3-319-05392-9_39  0.72
2015 Hartung HP. Local Anesthetic Activity Drug Discovery and Evaluation: Pharmacological Assay, Fourth Edition. 1717-1766. DOI: 10.1007/978-3-319-05392-9_38  0.72
2015 Gold R, Gass A, Haupts M, Linker R, Lukas C, Mäurer M, Stangel M, Tackenberg B, Ziemssen T, Wiendl H, Hartung HP, Haas J, Harms L, Honig H, Kallmann B, et al. Therapy and management of relapsing-remitting multiple sclerosis | Therapieziele und Therapie - management bei schubförmigremittierender Multipler Sklerose Nervenheilkunde. 34: 915-923.  0.72
2014 Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA. Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). Multiple Sclerosis and Related Disorders. 3: 355-63. PMID 25876473 DOI: 10.1016/j.msard.2013.11.006  0.72
2014 Hartmann CJ, Klistorner AI, Brandt AU, Schroeder K, Kolbe R, Cohn E, Goebels N, Guthoff R, Aktas O, Hartung HP, Albrecht P. Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. PMID 25613033 DOI: 10.1016/j.clinph.2014.12.014  0.72
2014 Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O. Subtle retinal pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 1: 290-7. PMID 25590041 DOI: 10.1002/acn3.46  0.72
2014 Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, Jarius S, Aktas O. Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. Bmc Neurology. 14: 247. PMID 25516429 DOI: 10.1186/s12883-014-0247-3  0.4
2014 Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC. Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Neurology. 83: 2153-7. PMID 25361781 DOI: 10.1212/WNL.0000000000001049  0.72
2014 Meyer zu Hörste G, Cordes S, Mausberg AK, Zozulya AL, Wessig C, Sparwasser T, Mathys C, Wiendl H, Hartung HP, Kieseier BC. FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. Plos One. 9: e108756. PMID 25286182 DOI: 10.1371/journal.pone.0108756  0.72
2014 Meyer zu Horste G, Mausberg AK, Cordes S, El-Haddad H, Partke HJ, Leussink VI, Roden M, Martin S, Steinman L, Hartung HP, Kieseier BC. Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. Journal of Immunology (Baltimore, Md. : 1950). 193: 2678-90. PMID 25108020 DOI: 10.4049/jimmunol.1400367  0.72
2014 Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, Lehmann HC. IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Journal of Neuroimmunology. 274: 225-9. PMID 25002077 DOI: 10.1016/j.jneuroim.2014.06.007  0.72
2014 Weber A, Zimmermann C, Kieseier BC, Hartung HP, Hofstetter HH. Bacteria and their cell wall components uniformly co-activate interleukin-17-producing thymocytes. Clinical and Experimental Immunology. 178: 504-15. PMID 24995465 DOI: 10.1111/cei.12414  0.72
2014 Stüve O, Warnke C, Deason K, Stangel M, Kieseier BC, Hartung HP, von Büdingen HC, Centonze D, Forsthuber TG, Knappertz V. CD19 as a molecular target in CNS autoimmunity. Acta Neuropathologica. 128: 177-90. PMID 24993505 DOI: 10.1007/s00401-014-1313-z  0.72
2014 Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 83: 87-97. PMID 24920854 DOI: 10.1212/WNL.0000000000000540  0.72
2014 Hartung HP. Interferon β-1a for multiple sclerosis: old drug, new clothes. The Lancet. Neurology. 13: 638-9. PMID 24878062 DOI: 10.1016/S1474-4422(14)70100-0  0.72
2014 Prestel J, Volkers P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B. Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiology and Drug Safety. 23: 1192-204. PMID 24817531 DOI: 10.1002/pds.3638  0.72
2014 Hartung HP, Kieseier BC. The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives. Current Opinion in Neurology. 27: 243-5. PMID 24751962 DOI: 10.1097/WCO.0000000000000101  0.72
2014 Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, Pawlita M, Kümpfel T, Mäurer M, Stangel M, Wegner F, Hohlfeld R, Straeten V, Limmroth V, Weber T, ... ... Hartung HP, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology. 76: 792-801. PMID 24729444 DOI: 10.1002/ana.24153  0.72
2014 Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 82: 1491-8. PMID 24682966 DOI: 10.1212/WNL.0000000000000355  0.72
2014 Stettner M, Lohmann B, Wolffram K, Weinberger JP, Dehmel T, Hartung HP, Mausberg AK, Kieseier BC. Interleukin-17 impedes Schwann cell-mediated myelination. Journal of Neuroinflammation. 11: 63. PMID 24678820 DOI: 10.1186/1742-2094-11-63  0.72
2014 Lill CM, Schilling M, Ansaloni S, Schröder J, Jaedicke M, Luessi F, Schjeide BM, Mashychev A, Graetz C, Akkad DA, Gerdes LA, Kroner A, Blaschke P, Hoffjan S, Winkelmann A, ... ... Hartung HP, et al. Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics. 15: 129-34. PMID 24638856 DOI: 10.1007/s10048-014-0396-y  0.72
2014 Derksen A, Ritter C, Athar P, Kieseier BC, Mancias P, Hartung HP, Sheikh KA, Lehmann HC. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle & Nerve. 50: 780-4. PMID 24616124 DOI: 10.1002/mus.24226  0.72
2014 Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet. Neurology. 13: 353-63. PMID 24613349 DOI: 10.1016/S1474-4422(14)70028-6  0.72
2014 Matusch A, Saft C, Elmenhorst D, Kraus PH, Gold R, Hartung HP, Bauer A. Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease. European Journal of Nuclear Medicine and Molecular Imaging. 41: 1210-20. PMID 24566949 DOI: 10.1007/s00259-014-2724-8  0.72
2014 Hartung HP, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. Handbook of Clinical Neurology. 122: 3-14. PMID 24507511 DOI: 10.1016/B978-0-444-52001-2.00001-7  0.72
2014 Dehmel T, Döbert M, Pankratz S, Leussink VI, Hartung HP, Wiendl H, Kieseier BC. Monomethylfumarate reduces in vitro migration of mononuclear cells Neurological Sciences. 35: 1121-1125. PMID 24504620 DOI: 10.1007/s10072-014-1663-2  0.72
2014 Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. The Lancet. Neurology. 13: 257-67. PMID 24502830 DOI: 10.1016/S1474-4422(14)70005-5  0.72
2014 Doerner M, Beckmann K, Knappertz V, Kappos L, Hartung HP, Filippi M, O'Connor PW, Arnason B, Cook S, Jeffery D, Comi G, Limmroth V. Effects of inhibitors of the renin-angiotensin system on the efficacy of interferon beta-1b: a post hoc analysis of the BEYOND study. European Neurology. 71: 173-9. PMID 24457374 DOI: 10.1159/000355530  0.72
2014 Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. Jama Neurology. 71: 306-14. PMID 24445558 DOI: 10.1001/jamaneurol.2013.5993  0.72
2014 Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology. 7: 91-104. PMID 24325127 DOI: 10.1586/17512433.2014.865517  0.72
2014 Clanet MC, Wolinsky JS, Ashton RJ, Hartung HP, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1306-11. PMID 24293456 DOI: 10.1177/1352458513513207  0.72
2014 Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, Greenberg BM, Hemmer B, Stüve O. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clinical and Experimental Immunology. 175: 397-407. PMID 24102425 DOI: 10.1111/cei.12206  0.72
2014 Ringelstein M, Kleiter I, Ayzenberg I, Borisow N, Paul F, Ruprecht K, Kraemer M, Cohn E, Wildemann B, Jarius S, Hartung HP, Aktas O, Albrecht P. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 617-20. PMID 24009163 DOI: 10.1177/1352458513503053  0.72
2014 Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 234-42. PMID 23842212 DOI: 10.1177/1352458513494491  0.72
2014 Ringelstein M, Metz I, Ruprecht K, Koch A, Rappold J, Ingwersen J, Mathys C, Jarius S, Brück W, Hartung HP, Paul F, Aktas O. Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder Multiple Sclerosis Journal. 20: 882-888. DOI: 10.1177/1352458513510981  0.72
2014 Ringelstein M, Aktas O, Harmel J, Prayer D, Jarius S, Wildemann B, Hartung HP, Salhofer-Polanyi S, Leutmezer F, Rommer PS. Contribution of spinal cord biopsy to the differential diagnosis of longitudinal extensive transverse myelitis | Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica Der Nervenarzt. DOI: 10.1007/s00115-014-4137-0  0.72
2014 Gerbershagen K, Limmroth V, Hartung HP. Alemtuzumab: A new option in the therapy of relapsing-remitting multiple sclerosis | Alemtuzumab: Neue option in der therapie der schubformigen multiplen sklerose Psychopharmakotherapie. 21: 191-197.  0.72
2014 Baum K, Boldt HJ, Chan A, Harms L, Hartung HP, Kieseier BC, Korn T, Mäurer M, Meier U, Schreiber H, Tackenberg B, Wiendl H, Ziemssen T, Gold R. Dimethylfumarate as therapy for relapsing-remitting multiple sclerosis | Dimethylfumarat in der therapie der schubförmigen MS: Verträglichkeit und management von nebenwirkungen Nervenheilkunde. 33: 175-179.  0.72
2013 Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 81: 1400-8. PMID 24049136 DOI: 10.1212/WNL.0b013e3182a84101  0.72
2013 Jadasz JJ, Kremer D, Göttle P, Tzekova N, Domke J, Rivera FJ, Adjaye J, Hartung HP, Aigner L, Küry P. Mesenchymal stem cell conditioning promotes rat oligodendroglial cell maturation. Plos One. 8: e71814. PMID 23951248 DOI: 10.1371/journal.pone.0071814  0.72
2013 Weber A, Zimmermann C, Meyer Zu Hörste G, Kieseier BC, Hartung HP, Hofstetter HH. Bacterial flagellin and diphtheria toxin co-stimulate IL-17-producing thymocytes. Cytokine. 64: 221-6. PMID 23932883 DOI: 10.1016/j.cyto.2013.06.318  0.72
2013 Lehmann HC, Hughes RA, Hartung HP. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Handbook of Clinical Neurology. 115: 415-27. PMID 23931793 DOI: 10.1016/B978-0-444-52902-2.00023-0  0.72
2013 Ringelstein M, Harmel J, Distelmaier F, Ingwersen J, Menge T, Hellwig K, Kieseier B, Mayatepek E, Hartung HP, Kuempfel T, Aktas O. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: Infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum Multiple Sclerosis Journal. 19: 1544-1547. PMID 23886825 DOI: 10.1177/1352458513498125  0.72
2013 Shenoy AR, Dehmel T, Stettner M, Kremer D, Kieseier BC, Hartung HP, Hofstetter HH. Citalopram suppresses thymocyte cytokine production. Journal of Neuroimmunology. 262: 46-52. PMID 23886473 DOI: 10.1016/j.jneuroim.2013.06.006  0.72
2013 Weber A, Zimmermann C, Mausberg AK, Kieseier BC, Hartung HP, Hofstetter HH. Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimodâ„¢. International Immunopharmacology. 17: 427-31. PMID 23867290 DOI: 10.1016/j.intimp.2013.06.023  0.72
2013 Kremer D, Schichel T, Förster M, Tzekova N, Bernard C, van der Valk P, van Horssen J, Hartung HP, Perron H, Küry P. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Annals of Neurology. 74: 721-32. PMID 23836485 DOI: 10.1002/ana.23970  0.72
2013 Pfeifenbring S, Metz I, Kremer D, Küry P, Hartung HP, Brück W. Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions. Glia. 61: 1250-60. PMID 23828667 DOI: 10.1002/glia.22512  0.72
2013 Warnke C, Kieseier BC, Hartung HP. Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards. Journal of Neural Transmission (Vienna, Austria : 1996). 120: S55-60. PMID 23793997 DOI: 10.1007/s00702-013-1055-4  0.72
2013 Buttmann M, Kaveri S, Hartung HP. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends in Pharmacological Sciences. 34: 445-57. PMID 23791035 DOI: 10.1016/j.tips.2013.05.009  0.72
2013 Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, Stüve O, Rieckmann P, Montalban X, Ziemssen T, Auberson LZ, Pohlmann H, Mercier F, Dahlke F, Wallström E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. The Lancet. Neurology. 12: 756-67. PMID 23764350 DOI: 10.1016/S1474-4422(13)70102-9  0.72
2013 Stettner M, Wolffram K, Mausberg AK, Albrecht P, Derksen A, Methner A, Dehmel T, Hartung HP, Dietrich H, Kieseier BC. Promoting myelination in an in vitro mouse model of the peripheral nervous system: the effect of wine ingredients [corrected]. Plos One. 8: e66079. PMID 23762469 DOI: 10.1371/journal.pone.0066079  0.72
2013 Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, Ortiz MA, Pérez J, Damotte V, Booth D, Lopez de Lapuente A, Broer L, Schilling M, Akkad DA, Aktas O, ... ... Hartung HP, et al. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain : a Journal of Neurology. 136: 1778-82. PMID 23739915 DOI: 10.1093/brain/awt101  0.72
2013 Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, et al. Interleukin 17F level and interferon β response in patients with multiple sclerosis. Jama Neurology. 70: 1017-21. PMID 23732754 DOI: 10.1001/jamaneurol.2013.192  0.72
2013 Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O. The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. Journal of Neuroinflammation. 10: 67. PMID 23705890 DOI: 10.1186/1742-2094-10-67  0.72
2013 Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschle K, Klumbies K, Bellmann-Strobl J, Harmel J, Ruprecht K, Schippling S, Hartung HP, Aktas O, Brandt AU, Paul F. Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1887-95. PMID 23702433 DOI: 10.1177/1352458513489757  0.72
2013 Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H, Kieseier BC. Teriflunomide for treatment of multiple sclerosis | Teriflunomid zur Behandlung der Multiplen Sklerose Nervenarzt. 84: 724-731. PMID 23695001 DOI: 10.1007/s00115-013-3779-7  0.72
2013 Hartung HP, Haas J, Meergans M, Tracik F, Ortler S. Interferon-β1b in multiple sclerosis therapy: More than 20 years clinical experience | Interferon-β1b in der Multiple-Sklerose-Therapie: Mehr als 20 Jahre klinische Erfahrung Nervenarzt. 84: 679-704. PMID 23669866 DOI: 10.1007/s00115-013-3781-0  0.72
2013 Haupts MR, Haug C, Seidel D, Hartung HP. [Multimodal complex treatment in advanced multiple sclerosis]. Der Nervenarzt. 84: 723. PMID 23619981 DOI: 10.1007/s00115-013-3787-7  0.72
2013 Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Jama Neurology. 70: 390-3. PMID 23599943 DOI: 10.1001/jamaneurol.2013.668  0.72
2013 Zimmermann C, Weber A, Mausberg AK, Kieseier BC, Hartung HP, Hofstetter HH. T cell activation status determines the cytokine pattern induced by zymosan and bacterial DNA both in thymocytes and splenocytes. Clinical and Experimental Immunology. 172: 245-53. PMID 23574321 DOI: 10.1111/cei.12037  0.72
2013 Mathys C, Aissa J, Meyer Zu Hörste G, Reichelt DC, Antoch G, Turowski B, Hartung HP, Sheikh KA, Lehmann HC. Peripheral neuropathy: assessment of proximal nerve integrity by diffusion tensor imaging. Muscle & Nerve. 48: 889-96. PMID 23532987 DOI: 10.1002/mus.23855  0.72
2013 Lampl C, Nagl S, Arnason B, Comi G, O Connor P, Cook S, Jeffery D, Kappos L, Filippi M, Beckmann K, Bogumil T, Pohl C, Sandbrink R, Hartung HP. Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. Journal of Neurology. 260: 1838-45. PMID 23504050 DOI: 10.1007/s00415-013-6888-0  0.72
2013 Warnke C, Pawlita M, Dehmel T, Posevitz-Fejfar A, Hartung HP, Wiendl H, Kieseier BC, Adams O. An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1137-44. PMID 23388163 DOI: 10.1177/1352458513475489  0.72
2013 Jantzen SU, Ferrea S, Wach C, Quasthoff K, Illes S, Scherfeld D, Hartung HP, Seitz RJ, Dihné M. In vitro neuronal network activity in NMDA receptor encephalitis. Bmc Neuroscience. 14: 17. PMID 23379293 DOI: 10.1186/1471-2202-14-17  0.72
2013 Kieseier BC, Hartung HP. Targeting two-pore domain potassium channels - a promising strategy for treating T cell mediated autoimmunity. Experimental Neurology. 247: 286-8. PMID 23353639 DOI: 10.1016/j.expneurol.2013.01.016  0.72
2013 Lill CM, Schjeide BM, Graetz C, Liu T, Damotte V, Akkad DA, Blaschke P, Gerdes LA, Kroner A, Luessi F, Cournu-Rebeix I, Hoffjan S, Winkelmann A, Touze E, Pico F, ... ... Hartung HP, et al. Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. Journal of Medical Genetics. 50: 140-3. PMID 23315543 DOI: 10.1136/jmedgenet-2012-101411  0.72
2013 Mausberg AK, Dorok M, Stettner M, Müller M, Hartung HP, Dehmel T, Warnke C, Meyer Zu Hörste G, Kieseier BC. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology. 80: 296-303. PMID 23269592 DOI: 10.1212/WNL.0b013e31827debad  0.72
2013 Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion On Pharmacotherapy. 14: 123-36. PMID 23256518 DOI: 10.1517/14656566.2013.754012  0.72
2013 Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 1074-83. PMID 23234810 DOI: 10.1177/1352458512469695  0.72
2013 Lee JI, Macht S, Albrecht P, Hartung HP, Goebels N. Brachial amyotrophic diparesis associated with anti-Hu positive anterior horn cell disease and autonomic disorder. Journal of Neurology. 260: 301-2. PMID 23135291 DOI: 10.1007/s00415-012-6711-3  0.72
2013 Vanhoutte EK, Latov N, Deng C, Hanna K, Hughes RA, Bril V, Dalakas MC, Donofrio P, van Doorn PA, Hartung HP, Merkies IS. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 20: 748-55. PMID 22891893 DOI: 10.1111/j.1468-1331.2012.03851.x  0.72
2013 Krogias C, Tsivgoulis G, Grond M, Hartung HP, Hemmer B, Oertel W, Wiendl H, Gold R. Review and analysis of international case-control studies on CCSVI and multiple sclerosis | Übersicht und Analyse internationaler Fall-Kontroll-Studien zu "chronischen zerebrospinalen venösen Insuffizienz" (CCSVI) und Multipler Sklerose Aktuelle Neurologie. 40: 445-451. DOI: 10.1055/s-0033-1351271  0.72
2013 Gold R, Hartung HP. Long-term therapy with fingolimod for relapsing MS: 5-year safety and efficacy data of a phase II extension study | Langzeittherapie mit Fingolimod bei schubförmiger MS: Sicherheits- und Wirksamkeitsdaten einer Phase-II-Extensionsstudie nach 5 Jahren Aktuelle Neurologie. 40: 79-84. DOI: 10.1055/s-0033-1333778  0.72
2012 Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O. Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply. Archives of Neurology. 69: 1085-6. PMID 23753805 DOI: 10.1001/archneurol.2012.1316  0.72
2012 Lehmann HC, Hughes RA, Kieseier BC, Hartung HP. Recent developments and future directions in Guillain-Barré syndrome. Journal of the Peripheral Nervous System : Jpns. 17: 57-70. PMID 23279434 DOI: 10.1111/j.1529-8027.2012.00433.x  0.72
2012 Jaerve A, Kruse F, Malik K, Hartung HP, Müller HW. Age-dependent modulation of cortical transcriptomes in spinal cord injury and repair. Plos One. 7: e49812. PMID 23236355 DOI: 10.1371/journal.pone.0049812  0.72
2012 Haas J, Linker RA, Hartung HP, Meergans M, Ortler S, Tracik F. Fingolimod compassionate use program: Case study on the concept of a therapy option for multiple sclerosis prior to marketing approval | Fingolimod-Compassionate-use-Programm: Fallstudie zum Konzept einer Therapieoption bei Multipler Sklerose vor Zulassung und Markteinführung Nervenarzt. 83: 1575-1581. PMID 23203160 DOI: 10.1007/s00115-012-3612-8  0.72
2012 Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clinical Therapeutics. 34: 2268-78. PMID 23200102 DOI: 10.1016/j.clinthera.2012.11.006  0.72
2012 Stettner M, Albrecht P, Derksen A, Hartmann C, Turowski B, Neuen-Jacob E, Hartung HP, Kieseier BC, Arendt G. Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis. Bmj Case Reports. 2012. PMID 23175006 DOI: 10.1136/bcr-2012-006844  0.72
2012 Albrecht P, Müller AK, Ringelstein M, Finis D, Geerling G, Cohn E, Aktas O, Hartung HP, Hefter H, Methner A. Retinal neurodegeneration in Wilson's disease revealed by spectral domain optical coherence tomography. Plos One. 7: e49825. PMID 23166778 DOI: 10.1371/journal.pone.0049825  0.72
2012 Fernandez O, Berger T, Hartung HP, Putzki N. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis. Expert Review of Clinical Pharmacology. 5: 649-65. PMID 23146002 DOI: 10.1586/ecp.12.59  0.72
2012 Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (London, England). 380: 1819-28. PMID 23122652 DOI: 10.1016/S0140-6736(12)61769-3  0.72
2012 Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (London, England). 380: 1829-39. PMID 23122650 DOI: 10.1016/S0140-6736(12)61768-1  0.72
2012 Albrecht P, Stettner M, Husseini L, Macht S, Jander S, Mackenzie C, Oesterlee U, Slotty P, Methner A, Hartung HP, Aktas O. An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess. Bmc Neurology. 12: 133. PMID 23121862 DOI: 10.1186/1471-2377-12-133  0.72
2012 Gliem M, Hermsen D, Van Rooijen N, Hartung HP, Jander S. Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: An experimental study in mice Stroke. 43: 3352-3357. PMID 23117725 DOI: 10.1161/STROKEAHA.112.666818  0.72
2012 Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, ... ... Hartung HP, et al. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. Journal of Medical Genetics. 49: 558-62. PMID 22972946 DOI: 10.1136/jmedgenet-2012-101175  0.72
2012 Walter J, Hartung HP, Dihné M. Interferon gamma and sonic hedgehog signaling are required to dysregulate murine neural stem/precursor cells. Plos One. 7: e43338. PMID 22952668 DOI: 10.1371/journal.pone.0043338  0.72
2012 Jadasz JJ, Rivera FJ, Taubert A, Kandasamy M, Sandner B, Weidner N, Aktas O, Hartung HP, Aigner L, Küry P. p57kip2 regulates glial fate decision in adult neural stem cells Development (Cambridge). 139: 3306-3315. PMID 22874918 DOI: 10.1242/dev.074518  0.72
2012 Torres KJ, Göttle P, Kremer D, Rivera JF, Aguirre-Cruz L, Corona T, Hartung HP, Küry P. Vinpocetine inhibits oligodendroglial precursor cell differentiation Cellular Physiology and Biochemistry. 30: 711-722. PMID 22854710 DOI: 10.1159/000341451  0.72
2012 Heinen A, Tzekova N, Graffmann N, Torres KJ, Uhrberg M, Hartung HP, Küry P. Histone methyltransferase enhancer of zeste homolog 2 regulates Schwann cell differentiation. Glia. 60: 1696-708. PMID 22821416 DOI: 10.1002/glia.22388  0.72
2012 Mentzer D, Prestel J, Adams O, Gold R, Hartung HP, Hengel H, Kieseier BC, Ludwig WD, Keller-Stanislawski B. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. Journal of Neurology, Neurosurgery, and Psychiatry. 83: 927-33. PMID 22807558 DOI: 10.1136/jnnp-2012-302478  0.72
2012 Benedict RH, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung H, Krupp L, Penner I, Reder AT, Langdon D. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. Bmc Neurology. 12: 55. PMID 22799620 DOI: 10.1186/1471-2377-12-55  0.72
2012 Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, Kovacs Z, Lewerenz J, Lisak D, Maher P, Mausberg AK, Quasthoff K, Zimmermann C, Hartung HP, Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. Journal of Neuroinflammation. 9: 163. PMID 22769044 DOI: 10.1186/1742-2094-9-163  0.72
2012 Köhne A, Stettner M, Jangouk P, Dehmel T, Hartung HP, Lehmann HC, Kieseier BC. Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies? Archives of Neurology. 69: 1280-9. PMID 22751954 DOI: 10.1001/archneurol.2012.394  0.72
2012 Hochmeister S, Romauch M, Bauer J, Seifert-Held T, Weissert R, Linington C, Hartung HP, Fazekas F, Storch MK. Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination Experimental Neurology. 237: 70-77. PMID 22735489 DOI: 10.1016/j.expneurol.2012.06.010  0.72
2012 Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B, Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 79: 285-7. PMID 22722628 DOI: 10.1212/WNL.0b013e31825fdead  0.72
2012 Gliem M, Mausberg AK, Lee JI, Simiantonakis I, Van Rooijen N, Hartung HP, Jander S. Macrophages prevent hemorrhagic infarct transformation in murine stroke models Annals of Neurology. 71: 743-752. PMID 22718543 DOI: 10.1002/ana.23529  0.72
2012 Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, et al. Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. Journal of Neuroinflammation. 9: 129. PMID 22703536 DOI: 10.1186/1742-2094-9-129  0.72
2012 Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, Knappertz V, Pohl C, Hartung HP, Shah D, Miller JD, Sandbrink R, Lanius V, Gondek K, Russell MW. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis. Clinical Therapeutics. 34: 1132-44. PMID 22541587 DOI: 10.1016/j.clinthera.2012.03.004  0.72
2012 Nolting T, Lindecke A, Hartung HP, Koutsilieri E, Maschke M, Husstedt IW, Sopper S, Stüve O, Arendt G. Cytokine levels in CSF and neuropsychological performance in HIV patients Journal of Neurovirology. 18: 157-161. PMID 22528475 DOI: 10.1007/s13365-012-0091-4  0.72
2012 Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC. [Guillain-Barré syndrome after exposure to influenza]. Der Nervenarzt. 83: 714-30. PMID 22528062 DOI: 10.1007/s00115-012-3479-8  0.72
2012 Albrecht P, Müller AK, Südmeyer M, Ferrea S, Ringelstein M, Cohn E, Aktas O, Dietlein T, Lappas A, Foerster A, Hartung HP, Schnitzler A, Methner A. Optical coherence tomography in parkinsonian syndromes. Plos One. 7: e34891. PMID 22514688 DOI: 10.1371/journal.pone.0034891  0.72
2012 Hartung HP. Advances in the management of multiple sclerosis-related spasticity Expert Review of Neurotherapeutics. 12: 1. PMID 22509984 DOI: 10.1586/ern.12.10  0.72
2012 Lehmann HC, Hartung HP. Progress in untying the Gordian nodes of Ranvier in Guillain-Barré Syndrome. Experimental Neurology. 235: 211-3. PMID 22449474 DOI: 10.1016/j.expneurol.2012.03.001  0.72
2012 Schwarz CS, Ferrea S, Quasthoff K, Walter J, Görg B, Häussinger D, Schnitzler A, Hartung HP, Dihné M. Ammonium chloride influences in vitro-neuronal network activity. Experimental Neurology. 235: 368-73. PMID 22421534 DOI: 10.1016/j.expneurol.2012.02.019  0.72
2012 Smolianov V, Dehmel T, Kieseier BC, Hemmer B, Hartung HP, Hofstetter HH. Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6 Cytokine. 58: 231-237. PMID 22342156 DOI: 10.1016/j.cyto.2012.01.010  0.72
2012 Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis Nature Reviews Neurology. 8: 143-151. PMID 22270022 DOI: 10.1038/nrneurol.2012.8  0.72
2012 Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP. Alemtuzumab: A further option for treatment of multiple sclerosis | Alemtuzumab: Eine weitere chance zur therapie der multiplen sklerose Nervenarzt. 83: 487-501. PMID 22038387 DOI: 10.1007/s00115-011-3393-5  0.72
2012 Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken T, Buck D, Hartung HP, Holsboer F, Müller-Myhsok B, Hemmer B. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients. The Pharmacogenomics Journal. 12: 238-45. PMID 21502966 DOI: 10.1038/tpj.2011.14  0.72
2012 Brandt AU, Zimmermann H, Kaufhold F, Promesberger J, Schippling S, Finis D, Aktas O, Geis C, Ringelstein M, Ringelstein EB, Hartung HP, Paul F, Kleffner I, Dörr J. Patterns of retinal damage facilitate differential diagnosis between Susac syndrome and MS Plos One. 7. DOI: 10.1371/journal.pone.0038741  0.72
2012 Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC. Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity Therapeutic Advances in Neurological Disorders. 5: 255-266. DOI: 10.1177/1756285612453972  0.72
2012 Gold R, Hartung HP, Stangel M, Wiendl H, Zipp F. Therapeutic goals of baseline and escalation therapy for relapsing-Remitting multiple sclerosis | Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose Aktuelle Neurologie. 39: 342-350. DOI: 10.1055/s-0032-1305248  0.72
2012 Hughes R, Hartung HP. Authors' reply: Plasma exchange: Are bigger studies necessarily better? Nature Reviews Neurology. 8: 410. DOI: 10.1038/nrneurol.2011.59-c2  0.72
2012 Schwarz CS, Ferrea S, Quasthoff K, Walter J, Görg B, Häussinger D, Schnitzler A, Hartung HP, Dihné M. Corrigendum to "Ammonium chloride influences in vitro-neuronal network activity" [Experimental Neurology 235/1 (2008) 368-373] Experimental Neurology. 236: 240. DOI: 10.1016/j.expneurol.2012.05.009  0.72
2012 Husseini L, Leussink VI, Warnke C, Hartung HP, Kieseier BC. Cannabinoids for symptomatic therapy of multiple sclerosis | Cannabinoidezur symptomatischen therapie der multiplen sklerose Nervenarzt. 83: 695-704. DOI: 10.1007/s00115-011-3401-9  0.72
Low-probability matches
2018 Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, Köchert K, Pohl C, Arnason B, Comi G, Cook S, Filippi M, Hartung HP, Jeffery D, Kappos L, et al. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518763089. PMID 29521573 DOI: 10.1177/1352458518763089  0.24
2018 Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458517751049. PMID 29353550 DOI: 10.1177/1352458517751049  0.24
2016 Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England Journal of Medicine. PMID 28002688 DOI: 10.1056/NEJMoa1606468  0.24
2016 Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England Journal of Medicine. PMID 28002679 DOI: 10.1056/NEJMoa1601277  0.24
2016 Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. PMID 27511182 DOI: 10.1212/WNL.0000000000003078  0.24
2019 Neuhaus O, Wiesmüller KH, Hartung HP, Wiendl H. Prominent T-Cell Responses against the Acetylcholine Receptor Subunit in Myasthenia Gravis. Neurology Research International. 2019: 1969068. PMID 30941215 DOI: 10.1155/2019/1969068  0.2
2019 Amedonu E, Brenker C, Barman S, Schreiber JA, Becker S, Peischard S, Strutz-Seebohm N, Strippel C, Dik A, Hartung HP, Budde T, Wiendl H, Strünker T, Wünsch B, Goebels N, et al. An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. Frontiers in Neurology. 10: 178. PMID 30881339 DOI: 10.3389/fneur.2019.00178  0.2
2017 Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wrzos C, Demir F, Baksmeier C, Steckel J, Falk KK, Gross CC, Kovac S, Bönte K, Johnen A, ... ... Hartung HP, et al. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology. 4: 768-783. PMID 29159189 DOI: 10.1002/acn3.444  0.2
2017 Comi G, Hartung HP, Bakshi R, Williams IM, Wiendl H. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. Drugs. PMID 28905255 DOI: 10.1007/s40265-017-0814-1  0.2
2019 Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. The Lancet. Neurology. PMID 31492652 DOI: 10.1016/S1474-4422(19)30238-8  0.16
2019 Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. The Lancet. Neurology. PMID 31492651 DOI: 10.1016/S1474-4422(19)30239-X  0.16
2019 Dietrich M, Hecker C, Hilla A, Cruz-Herranz A, Hartung HP, Fischer D, Green A, Albrecht P. Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. Journal of Visualized Experiments : Jove. PMID 30688311 DOI: 10.3791/58571  0.16
2018 Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP, Berlit P, Laumer R, Diesner F. Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures. Journal of Neurology. PMID 30155735 DOI: 10.1007/s00415-018-9031-4  0.16
2018 Kraemer M, Sassen J, Karakaya R, Schwitalla JC, Graf J, Albrecht P, Hartung HP, Diehl RR, Berlit P, Laumer R, Diesner F. Moyamoya angiopathy: early postoperative course within 3 months after STA-MCA-bypass surgery in Europe-a retrospective analysis of 64 procedures. Journal of Neurology. PMID 30120561 DOI: 10.1007/s00415-018-8997-2  0.16
2018 Kraayvanger L, Berlit P, Albrecht P, Hartung HP, Kraemer M. Cerebrospinal Fluid Findings in Reversible Cerebral Vasoconstriction Syndrome - A way to differentiate from Cerebral Vasculitis? Clinical and Experimental Immunology. PMID 29722896 DOI: 10.1111/cei.13148  0.16
2018 Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, et al. Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. Annals of Clinical and Translational Neurology. 5: 346-356. PMID 29560379 DOI: 10.1002/acn3.534  0.16
2017 Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet. Neurology. PMID 29275977 DOI: 10.1016/S1474-4422(17)30470-2  0.16
2017 Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, ... ... Hartung HP, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. PMID 28916537 DOI: 10.1212/WNL.0000000000004485  0.16
2017 Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK. Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. International Journal of Molecular Sciences. 18. PMID 28800066 DOI: 10.3390/ijms18081749  0.16
2016 Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nature Reviews. Neurology. PMID 26943779 DOI: 10.1038/nrneurol.2016.21  0.16
2015 Winkelmann A, Löbermann M, Reisinger EC, Hartung HP, Zettl UK. Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs | Infektiologische Risiken in der Multiple-Sklerose-Therapie durch infundierbare Immuntherapeutika Nervenarzt. 86: 971-977. PMID 26187545 DOI: 10.1007/s00115-015-4388-4  0.16
2015 Winkelmann A, Löbermann M, Reisinger EC, Hartung HP, Zettl UK. Immunotherapy and infectious issues in multiple sclerosis: Self-injectable and oral drugs for immunotherapy | Immuntherapien und infektiologische Probleme bei Multipler Sklerose: Selbst injizierbare und orale Immuntherapeutika Nervenarzt. 86: 960-970. PMID 26187544 DOI: 10.1007/s00115-015-4369-7  0.16
2015 Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, Tomic D, Kappos L. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 26111826 DOI: 10.1136/jnnp-2015-310597  0.16
2019 Lin Y, Schulze V, Brockmeyer M, Parco C, Karathanos A, Heinen Y, Gliem M, Hartung HP, Antoch G, Jander S, Turowski B, Perings S, Kelm M, Wolff G. Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis. Jama Neurology. PMID 30958530 DOI: 10.1001/jamaneurol.2019.0525  0.12
2018 Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, ... ... Hartung HP, et al. Regional variation of Guillain-Barré syndrome. Brain : a Journal of Neurology. PMID 30247567 DOI: 10.1093/brain/awy232  0.12
2018 Lehmann HC, Compston A, Hartung HP. 150th anniversary of clinical description of multiple sclerosis: Leopold Ordenstein's legacy. Neurology. 90: 1011-1016. PMID 29807916 DOI: 10.1212/WNL.0000000000005613  0.12
2017 Lee JI, Gliem M, Gerdes G, Turowski B, Kaschner M, Kraus B, Hartung HP, Jander S. Safety of bridging antiplatelet therapy with the gpIIb-IIIa inhibitor tirofiban after emergency stenting in stroke. Plos One. 12: e0190218. PMID 29281734 DOI: 10.1371/journal.pone.0190218  0.12
2017 Gliem M, Lee JI, Barckhan A, Turowski B, Hartung HP, Jander S. Outcome and Treatment Effects in Stroke Associated with Acute Cervical ICA Occlusion. Plos One. 12: e0170247. PMID 28081270 DOI: 10.1371/journal.pone.0170247  0.12
2016 Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. Bmc Neurology. 16: 98. PMID 27405225 DOI: 10.1186/s12883-016-0625-0  0.12
2019 Hartung HP, Graf J, Kremer D. Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology. PMID 30610426 DOI: 10.1007/s00415-018-09169-w  0.08
2017 Sasidhar MV, Chevooru SK, Eickelberg O, Hartung HP, Neuhaus O. Downregulation of monocytic differentiation via modulation of CD147 by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Plos One. 12: e0189701. PMID 29253870 DOI: 10.1371/journal.pone.0189701  0.08
2016 Winter M, Baksmeier C, Steckel J, Barman S, Malviya M, Harrer-Kuster M, Hartung HP, Goebels N. Dose-dependent inhibition of demyelination and microglia activation by IVIG. Annals of Clinical and Translational Neurology. 3: 828-843. PMID 27844029 DOI: 10.1002/acn3.326  0.08
2015 Kremer D, Hartung HP, Stangel M, Küry P. New therapeutic strategies for remyelination in multiple sclerosis | Neue Therapiestrategien zur Myelinreparatur bei der Multiplen Sklerose Nervenarzt. 86: 934-946. PMID 26122637 DOI: 10.1007/s00115-014-4249-6  0.08
2019 Beyer F, Jadasz J, Samper Agrelo I, Schira-Heinen J, Groh J, Manousi A, Bütermann C, Estrada V, Reiche L, Cantone M, Vera J, Viganò F, Dimou L, Müller HW, Hartung HP, et al. Heterogeneous fate choice of genetically modulated adult neural stem cells in gray and white matter of the central nervous system. Glia. PMID 31633850 DOI: 10.1002/glia.23724  0.04
2019 Verboon C, van den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, Lingsma H, Van den Bergh P, Harbo T, Bateman K, Pereon Y, Sindrup SH, Kusunoki S, Miller J, Islam Z, ... Hartung HP, et al. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 31586949 DOI: 10.1136/jnnp-2019-321496  0.04
2019 Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology. PMID 31484710 DOI: 10.1212/WNL.0000000000008189  0.04
2019 van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurology(R) Neuroimmunology & Neuroinflammation. 6. PMID 31454770 DOI: 10.1212/NXI.0000000000000590  0.04
2019 Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study. European Journal of Neurology. PMID 31400231 DOI: 10.1111/ene.14056  0.04
2019 Gruchot J, Weyers V, Göttle P, Förster M, Hartung HP, Küry P, Kremer D. The Molecular Basis for Remyelination Failure in Multiple Sclerosis. Cells. 8. PMID 31382620 DOI: 10.3390/cells8080825  0.04
2019 van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurology(R) Neuroimmunology & Neuroinflammation. 6: e590. PMID 31355323 DOI: 10.1212/NXI.0000000000000590  0.04
2019 Kremer D, Gruchot J, Weyers V, Oldemeier L, Göttle P, Healy L, Ho Jang J, Kang T Xu Y, Volsko C, Dutta R, Trapp BD, Perron H, Hartung HP, Küry P. pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. PMID 31213545 DOI: 10.1073/pnas.1901283116  0.04
2019 Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Current Opinion in Neurology. PMID 30985372 DOI: 10.1097/WCO.0000000000000700  0.04
2019 Kremer D, Göttle P, Flores-Rivera J, Hartung HP, Küry P. Remyelination in multiple sclerosis: from concept to clinical trials. Current Opinion in Neurology. PMID 30865009 DOI: 10.1097/WCO.0000000000000692  0.04
2019 Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, et al. Efficacy and safety of IVIG in CIDP: combined data of the PRIMA and PATH studies. Journal of the Peripheral Nervous System : Jpns. PMID 30672091 DOI: 10.1111/jns.12302  0.04
2019 Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN. Restabilization treatment after IVIG withdrawal in chronic inflammatory demyelinating polyneuropathy. Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra® (PATH) study. Journal of the Peripheral Nervous System : Jpns. PMID 30672067 DOI: 10.1111/jns.12303  0.04
2018 Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P. Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201801799R. PMID 30592632 DOI: 10.1096/fj.201801799R  0.04
2018 Göttle P, Förster M, Gruchot J, Kremer D, Hartung HP, Perron H, Küry P. Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. Glia. PMID 30430656 DOI: 10.1002/glia.23535  0.04
2018 Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, ... ... Hartung HP, et al. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. Brain Imaging and Behavior. PMID 30155789 DOI: 10.1007/s11682-018-9942-9  0.04
2018 Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518789884. PMID 30043658 DOI: 10.1177/1352458518789884  0.04
2018 Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. The Lancet. Neurology. PMID 30001923 DOI: 10.1016/S1474-4422(18)30202-3  0.04
2018 Kremer D, Küry P, Hartung HP. ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518768770. PMID 29629605 DOI: 10.1177/1352458518768770  0.04
2018 Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA. A randomized, multicentre phase III study of three different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. Journal of the Peripheral Nervous System : Jpns. PMID 29603842 DOI: 10.1111/jns.12267  0.04
2018 Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 4: 2055217318760642. PMID 29568544 DOI: 10.1177/2055217318760642  0.04
2018 Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung HP, Perron H. Human Endogenous Retroviruses in Neurological Diseases. Trends in Molecular Medicine. PMID 29551251 DOI: 10.1016/j.molmed.2018.02.007  0.04
2018 Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. The Lancet. Neurology. PMID 29545067 DOI: 10.1016/S1474-4422(18)30069-3  0.04
2018 Göttle P, Manousi A, Kremer D, Reiche L, Hartung HP, Küry P. Teriflunomide promotes oligodendroglial differentiation and myelination. Journal of Neuroinflammation. 15: 76. PMID 29534752 DOI: 10.1186/s12974-018-1110-z  0.04
2018 Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G. Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology. PMID 29356206 DOI: 10.1111/ene.13581  0.04
2017 van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Neurology. PMID 29122523 DOI: 10.1016/S1474-4422(17)30378-2  0.04
2017 Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 3: 2055217317732802. PMID 29051829 DOI: 10.1177/2055217317732802  0.04
2017 Jadasz JJ, Tepe L, Beyer F, Samper Agrelo I, Akkermann R, Spitzhorn LS, Silva ME, Oreffo ROC, Hartung HP, Prigione A, Rivera FJ, Adjaye J, Küry P. Human mesenchymal factors induce rat hippocampal- and human neural stem cell dependent oligodendrogenesis. Glia. PMID 28940767 DOI: 10.1002/glia.23233  0.04
2017 Kremer D, Glanzman R, Traboulsee A, Nath A, Groc L, Horwitz M, Göttle P, Perron H, Gold J, Hartung HP, Küry P. Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017. Multiple Sclerosis and Related Disorders. 15: 18-23. PMID 28641767 DOI: 10.1016/j.msard.2017.05.001  0.04
2017 Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A. Sodium intake and multiple sclerosis activity and progression in BENEFIT. Annals of Neurology. PMID 28556498 DOI: 10.1002/ana.24965  0.04
2017 Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RA, Kusunoki S, van Doorn PA, Willison HJ. International Guillain-Barré Syndrome Outcome Study (IGOS):Protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. Journal of the Peripheral Nervous System : Jpns. PMID 28406555 DOI: 10.1111/jns.12209  0.04
2016 Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C. Repair strategies for multiple sclerosis: challenges, achievements and perspectives. Current Opinion in Neurology. PMID 27035897 DOI: 10.1097/WCO.0000000000000325  0.04
2016 Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 27003945 DOI: 10.1177/1352458516638941  0.04
2016 Kremer D, Cui QL, Göttle P, Kuhlmann T, Hartung HP, Antel J, Küry P. CXCR7 Is Involved in Human Oligodendroglial Precursor Cell Maturation. Plos One. 11: e0146503. PMID 26741980 DOI: 10.1371/journal.pone.0146503  0.04
2015 Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, et al. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. PMID 26239222 DOI: 10.1007/s00415-015-7862-9  0.04
2014 Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 1183-9. PMID 24218527 DOI: 10.1136/jnnp-2013-306222  0.04
2019 Haas J, Jeffery D, Silva D, Meier DP, Meinert R, Cohen J, Hartung HP. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders. 36: 101335. PMID 31557679 DOI: 10.1016/j.msard.2019.07.011  0.01
2019 Penner IK, Hartung HP. The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis. Brain : a Journal of Neurology. 142: 2552-2555. PMID 31497861 DOI: 10.1093/brain/awz234  0.01
2019 Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. The Lancet. Neurology. PMID 31285147 DOI: 10.1016/S1474-4422(19)30137-1  0.01
2019 Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458519841829. PMID 30986126 DOI: 10.1177/1352458519841829  0.01
2018 Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518796675. PMID 30289355 DOI: 10.1177/1352458518796675  0.01
2018 Haupts MR, Spill-Askeridis P, Humpert M, Seidel D, Hartung HP. Acute exacerbations after decades of non-active chronic multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 1352458518754365. PMID 29363379 DOI: 10.1177/1352458518754365  0.01
2017 Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. PMID 28835403 DOI: 10.1212/WNL.0000000000004354  0.01
2017 Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. PMID 28835401 DOI: 10.1212/WNL.0000000000004313  0.01
2017 Pilz G, Wipfler P, Schwarte O, Golaszewski S, McCoy M, Haschke-Becher E, Hartung HP, Kraus J. Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome. Journal of Neurology. PMID 28229242 DOI: 10.1007/s00415-017-8418-y  0.01
2016 Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. PMID 27733571 DOI: 10.1212/WNL.0000000000003319  0.01
2016 Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design. Multiple Sclerosis and Related Disorders. 9: 95-100. PMID 27645352 DOI: 10.1016/j.msard.2016.07.002  0.01
2016 van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. Trials. 17: 345. PMID 27455854 DOI: 10.1186/s13063-016-1466-2  0.01
2016 Cohen D, Hartung H, Evans P, Friedman DF, Chou ST. Red blood cell alloimmunization in transfused patients with bone marrow failure syndromes. Transfusion. PMID 27080340 DOI: 10.1111/trf.13608  0.01
2016 Hartung H, Brockmann MD, Pöschel B, De Feo V, Hanganu-Opatz IL. Thalamic and Entorhinal Network Activity Differently Modulates the Functional Development of Prefrontal-Hippocampal Interactions. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 3676-90. PMID 27030754 DOI: 10.1523/JNEUROSCI.3232-15.2016  0.01
2016 Reich K, Hartung HP, Lebwohl M. More on PML in Patients Treated with Dimethyl Fumarate. The New England Journal of Medicine. 374: 294-5. PMID 26789900 DOI: 10.1056/NEJMc1512228#SA1  0.01
2016 Geiss R, Sergeyev A, Hartung H, Solntsev AS, Sukhorukov AA, Grange R, Schrempel F, Kley EB, Tü Nnermann A, Pertsch T. Fabrication of free-standing lithium niobate nanowaveguides down to 50 nm in width Nanotechnology. 27. DOI: 10.1088/0957-4484/27/6/065301  0.01
2015 Paessler M, Hartung H. Dehydrated hereditary stomatocytosis masquerading as MDS Blood. 125: 1841. PMID 25927085 DOI: 10.1182/blood-2014-11-612184  0.01
2015 MacFarland S, Hartung H. Pancytopenia in a patient with methylmalonic acidemia Blood. 125: 1840. PMID 25927084 DOI: 10.1182/blood-2014-11-609479  0.01
2015 Babushok DV, Perdigones N, Perin JC, Olson TS, Ye W, Roth JJ, Lind C, Cattier C, Li Y, Hartung H, Paessler ME, Frank DM, Xie HM, Cross S, Cockroft JD, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genetics. 208: 115-28. PMID 25800665 DOI: 10.1016/j.cancergen.2015.01.007  0.01
2015 Lehr D, Reinhold J, Thiele I, Hartung H, Dietrich K, Menzel C, Pertsch T, Kley EB, Tünnermann A. Enhancing second harmonic generation in gold nanoring resonators filled with lithium niobate. Nano Letters. 15: 1025-30. PMID 25584636 DOI: 10.1021/nl5038819  0.01
2015 Ipe TS, Wilkes JJ, Hartung HD, Westhoff CM, Chou ST, Friedman DF. Severe hemolytic transfusion reaction due to anti-D in a D+ patient with sickle cell disease. Journal of Pediatric Hematology/Oncology. 37: e135-7. PMID 25171447 DOI: 10.1097/MPH.0000000000000241  0.01
2014 Hartung H, Akkerman P. Roofwater harvesting on the coastal islands of Guinea-Bissau: Rainwater tank construction adapted to the local context Waterlines. 33: 160-167. DOI: 10.3362/1756-3488.2014.017  0.01
2014 Hartung H. Fissure(s): Walking/dancing along, across and in-between lines of difference Performance Research. 19: 5-14. DOI: 10.1080/13528165.2014.985075  0.01
2013 Hartung HD, Olson TS, Bessler M. Acquired aplastic anemia in children. Pediatric Clinics of North America. 60: 1311-36. PMID 24237973 DOI: 10.1016/j.pcl.2013.08.011  0.01
2013 Exley R, Clements MA, Hartung H, McIntosh JM, Franklin M, Bermudez I, Cragg SJ. Striatal dopamine transmission is reduced after chronic nicotine with a decrease in α6-nicotinic receptor control in nucleus accumbens. The European Journal of Neuroscience. 38: 3036-43. PMID 23841846 DOI: 10.1111/ejn.12298  0.01
2013 Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Vander-Valk P, Gerdil C, Mancuso R, Saresella M, ... ... Hartung HP, et al. Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672]. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 831-2. PMID 23658240 DOI: 10.1177/1352458513485150  0.01
2013 Tan SK, Hartung H, Schievink S, Sharp T, Temel Y. High-frequency stimulation of the substantia nigra induces serotonin-dependent depression-like behavior in animal models. Biological Psychiatry. 73: e1-3. PMID 22939751 DOI: 10.1016/j.biopsych.2012.07.032  0.01
2013 Hartung HG, Kümmel L, Winklhofer K, Sasse C. Steel plates made of hot band as an economic alternative to plate mill products Aistech - Iron and Steel Technology Conference Proceedings. 2: 1609-1616.  0.01
2013 Sieben K, Hartung H, Wolff A, Hanganu-Opatz IL. The melody of the immature brain | Die melodie des unreifen gehirns Neuroforum. 19: 14-20.  0.01
2012 Siemieniuk RA, Power C, Gill MJ. Guillain-barré syndrome [11] New England Journal of Medicine. 367: 973-974. PMID 22931277 DOI: 10.1056/NEJMc1208413  0.01
2012 Hohlfeld O, Bayerer R, Hunger T, Hartung H. Stacked substrates for high voltage applications 2012 7th International Conference On Integrated Power Electronics Systems, Cips 2012 0.01
2012 Kiefer P, Matzer W, Schiestl S, Hartung H, Schwärzler I, Seunig R, Hofäcker J, Endler PC. Wheat germination and highly diluted agitated gibberellic acid (10- 30) - A multi researcher study International Journal of High Dilution Research. 11: 45-59.  0.01
1999 Auer-Grumbach M, Wagner K, Payer F, Hartung HP. Proximal Charcot-Marie-Tooth Syndrome with Duplication on Chromosome 17p11.2. Annals of the New York Academy of Sciences. 883: 469-471. PMID 29086978 DOI: 10.1111/j.1749-6632.1999.tb08613.x  0.01
Hide low-probability matches.